Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium

X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal phosphate wasting and impaired skeletal and dental mineralization. Recently, international guidelines for the diagnosis and treatment of this condition have been published. However, more specific recommendations are needed to provide guidance at the national level, considering resource availability and health economic aspects. A national multidiscip... Mehr ...

Verfasser: Laurent, Michaël R.
De Schepper, Jean
Trouet, Dominique
Godefroid, Nathalie
Boros, Emese
Heinrichs, Claudine
Bravenboer, Bert
Velkeniers, Brigitte
Lammens, Johan
Harvengt, Pol
Cavalier, Etienne
Kaux, Jean-François
Lombet, Jacques
De Waele, Kathleen
Verroken, Charlotte
van Hoeck, Koenraad
Mortier, Geert R.
Levtchenko, Elena
Vande Walle, Johan
Dokumenttyp: journalarticle
Erscheinungsdatum: 2021
Schlagwörter: Medicine and Health Sciences / Endocrinology / Diabetes and Metabolism / X-linked hypophosphatemia / XLH / rickets / burosumab / fibroblast growth factor 23 (FGF23) / osteomalacia / vitamin D / GROWTH-HORMONE TREATMENT / SHORT CHILDREN / EARLY-ONSET / PHOSPHATE / FGF23 / EXPRESSION / DISORDERS / PHENOTYPE / DENTIN
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28551924
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://biblio.ugent.be/publication/8748494